NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, due to alleged securities fraud [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [1]. - Investors who purchased Nektar securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must be appointed by May 5, 2026, to represent other class members in the litigation [1]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and ranking No. 1 for settlements in 2017 [1]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [1]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [1].